Veye Lung Nodules
AN EXAMPLE OF PACS INTEGRATION
*This is a test patient ID.
Lung nodule detection, quantification and growth assessment, fully integrated into the radiology workflow
Veye Lung Nodules
- >= 3mm and <=30mm in size
- Solid and sub-solid nodules (part-solid/ground-glass opacity)
- Diameters: long axis, perpendicular short axis, and the average axial diameter
- Volume: 3mm, per-slice segmentation and 3D visualisation
- Growth percentage
- Volume doubling time (VDT)
- Solid and sub-solid nodules
Veye Lung Nodules
Proven value for patients
Making a radiology assessment is much more than finding abnormalities on scans. Yet when reporting chest CT scans for lung nodules, you spend most of your time searching for millimetric lesions with the naked eye, counting, segmenting, and measuring them (semi-)manually.
Veye Lung Nodules is ready to assist you with all the time-consuming, tedious and error-prone tasks. Automated volumetry will further give you an insight into the evolution of a nodule.
In a case reported by a Dutch hospital, a nodule’s change in diameter seemed minor; thus, the radiologist was inclined not to follow up. Veye Lung Nodules, however, identified a significant volume growth, helping clinicians arrive at a timely lung cancer diagnosis.
Integrated into your workflow
Veye Lung Nodules runs in the background, automatically processing all eligible studies, including the most recent prior, if available. Its results are delivered directly to the PACS, as part of the original diagnostic series. The results are visible to anyone with PACS access, on or off-site. Or from home. Anytime.
When you start reading the scan, Veye Lung Nodules’ analysis is already present – there is no need for extra clicks, log-ins, and waiting time. Your workflow stays the same – while your reading is supported by powerful AI technology.
The clinical performance of Veye Lung Nodules has been validated in a study performed by the University of Edinburgh and NHS Lothian. On default settings, Veye detects nodules at a sensitivity of 91% at the cost of 1 false positive on average per scan. The performance has been confirmed by independent research at a large teaching hospital in the Netherlands.
Results from a study with two radiologists show an average ~ 40% reduction in reading time and higher reader agreement when reporting on pulmonary nodules with Veye.
Veye Lung Nodules supports the improvement of patient outcomes by delivering fast results, lowering the risk of misdiagnosis, and by detecting and segmenting possible early-stage lung cancer.
Trusted across Europe
Veye Lung Nodules is currently running in hospitals across Europe, analysing thousands of patient scans each week
In the UK, it is the AI solution of choice in NHS England’s Targeted Lung Health Checks, a nationwide lung cancer screening programme.
Veye has also been handpicked by AstraZeneca for the European PINPOINT project, aiming to increase early lung cancer diagnosis through better detection and follow-up of incidental pulmonary nodules.
Regardless of your hospital’s location in Europe, the Aidence service team offers dedicated, local training and support.
Are you ready to champion AI in your radiology team, or do you want to know more?
After learning from our real-world implementations, we can guide you on the path to AI adoption. Veye Lung Nodules is currently deployed in multiple hospitals across Europe, analysing thousands of scans each week.